The company was a standout in the biotech field, rising by nearly 23% over the period.
Caution: This company has had legal issues in the past. It is highly speculative. The Chart of the Day belongs to the oncology company Summit Therapeutics (SMMT) . I found the stock by using Barchart's...
/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...
/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...
The company's shares have been falling since it announced earnings late last week.
Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer.
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ:...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ:...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December...